Rheum Round-up: Interview with Dr. Keenan, Rixutimab Ups Severe COVID-19 Risk, PsA Drug Comparison
This week in the DocWire News rheumatology section, I interviewed Robert Keenan, MD, an adjunct associate professor at Duke University School of Medicine, Division...
Upadacitinib versus Adalimumab: How Do These Arthritis Drugs Compare?
A higher dose of upadacitinib was superior to adalimumab in patients with psoriatic arthritis, according to a study, but outcomes did not largely differ...
Rheum Round-up: Psoriatic Arthritis Medication Research, Hip Fracture Survival
Guselkumab Safe, Effective in Biologic-naïve Patients with Psoriatic Arthritis
Guselkumab was a safe and effective treatment for biologic-naïve patients with psoriatic arthritis (PsA), according to...
Guselkumab Safe, Effective in Biologic-naïve Patients with Psoriatic Arthritis
Guselkumab was a safe and effective treatment for biologic-naïve patients with psoriatic arthritis (PsA), according to one-year data from a phase 3 study.
“Guselkumab, a...
Ixekizumab Withdrawal In Psoriatic Arthritis May Result In Relapse
Patients with psoriatic arthritis (PsA) who achieved minimal disease activity on ixekizumab may relapse if they terminate treatment, according to a study.
SPIRIT-P3, a multicenter,...
Adalimumab Versus Biosimilar: How Do These Drugs Compare in RA, PsA, PsO?
An analysis of two studies comparing adalimumab biosimilar SDZ-ADL versus reference adalimumab in patient-reported outcomes (PROs) in patients with moderate‐to‐severe chronic plaque psoriasis (PsO),...
Which Arthritis Treatments Increase The Risk for COVID-19?
Glucocorticoids in the treatment of arthritis may increase the risk for COVID-19 infection, while targeted-synthetic/biological (ts/b) disease-modifying drugs (DMARDs) may reduce the risk, according...
